Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Mar 5;24(5):5010.
doi: 10.3390/ijms24055010.

Revisiting Host-Pathogen Interactions in Cystic Fibrosis Lungs in the Era of CFTR Modulators

Carla M P Ribeiro  1   2   3 , Matthew G Higgs  1   4 , Marianne S Muhlebach  1   5 , Matthew C Wolfgang  1   4 , Monica Borgatti  6   7 , Ilaria Lampronti  6   7 , Giulio Cabrini  6   7
Affiliations
Review

Revisiting Host-Pathogen Interactions in Cystic Fibrosis Lungs in the Era of CFTR Modulators

Carla M P Ribeiro et al. Int J Mol Sci. .

Abstract

Cystic fibrosis transmembrane conductance regulator (CFTR) modulators, a new series of therapeutics that correct and potentiate some classes of mutations of the CFTR, have provided a great therapeutic advantage to people with cystic fibrosis (pwCF). The main hindrances of the present CFTR modulators are related to their limitations in reducing chronic lung bacterial infection and inflammation, the main causes of pulmonary tissue damage and progressive respiratory insufficiency, particularly in adults with CF. Here, the most debated issues of the pulmonary bacterial infection and inflammatory processes in pwCF are revisited. Special attention is given to the mechanisms favoring the bacterial infection of pwCF, the progressive adaptation of Pseudomonas aeruginosa and its interplay with Staphylococcus aureus, the cross-talk among bacteria, the bronchial epithelial cells and the phagocytes of the host immune defenses. The most recent findings of the effect of CFTR modulators on bacterial infection and the inflammatory process are also presented to provide critical hints towards the identification of relevant therapeutic targets to overcome the respiratory pathology of pwCF.

Keywords: CFTR modulators; Pseudomonas aeruginosa; Staphylococcus aureus; airway epithelia; airway infection; airway inflammation; cystic fibrosis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Rommens J.M., Iannuzzi M.C., Kerem B., Drumm M.L., Melmer G., Dean M., Rozmahel R., Cole J.L., Kennedy D., Hidaka N., et al. Identification of the cystic fibrosis gene: Chromosome walking and jumping. Science. 1989;245:1059–1065. doi: 10.1126/science.2772657. - DOI - PubMed
    1. Riordan J.R., Rommens J.M., Kerem B., Alon N., Rozmahel R., Grzelczak Z., Zielenski J., Lok S., Plavsic N., Chou J.L., et al. Identification of the cystic fibrosis gene: Cloning and characterization of complementary DNA. Science. 1989;245:1066–1073. doi: 10.1126/science.2475911. - DOI - PubMed
    1. Kerem B., Rommens J.M., Buchanan J.A., Markiewicz D., Cox T.K., Chakravarti A., Buchwald M., Tsui L.C. Identification of the cystic fibrosis gene: Genetic analysis. Science. 1989;245:1073–1080. doi: 10.1126/science.2570460. - DOI - PubMed
    1. CFTR2. [(accessed on 20 December 2022)]. Available online: https://cftr2.org.
    1. Bell S.C., De Boeck K., Amaral M.D. New pharmacological approaches for cystic fibrosis: Promises, progress, pitfalls. Pharmacol. Ther. 2015;145:19–34. doi: 10.1016/j.pharmthera.2014.06.005. - DOI - PubMed

MeSH terms

Substances